Article Text

Download PDFPDF
Risk of bias in meta-analysis on erythropoietin-stimulating agents in heart failure
  1. B P Geisler1,2,3,
  2. R M van Dam1,4,5,
  3. G S Gazelle1,2,
  4. A Goehler2,3
  1. 1
    Harvard School of Public Health Boston, Massachusetts, USA
  2. 2
    Massachusetts General Hospital, Boston, Massachusetts, USA
  3. 3
    University for Health Sciences Medical Informatics and Technology, Hall, Austria
  4. 4
    Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA
  5. 5
    Boston Obesity Nutrition Research Center, Boston, Massachusetts, USA
  1. Dr B P Geisler, 38 Calvin St, Somerville, MA 02143, USA; ben.geisler{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To the editor: We are delighted by the encouraging results reported in the meta-analysis of van der Meer et al1 regarding lower hospitalisation rates for patients with heart failure (HF) receiving erythropoiesis-stimulating agents. However, the possibility of bias in the studies included in the meta-analysis might be greater than assessed by the authors.

First, the methodological quality of the …

View Full Text

Linked Articles

  • Featured correspondence
    P van der Meer D J van Veldhuisen